December 12, 2013 | BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, has announced that it was awarded an $800,000 non-dilutive grant from Israel’s Office of the Chief Scientist (OCS) for the year 2014. The grant is intended to support BrainStorm’s clinical and product development for its stem cell therapy candidate NurOwn.
Related posts
$10M For Cyber Company That Protects Small Businesses
January 31, 2023
Phone-Block Technology For School Bus Drivers
January 31, 2023
Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023
People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments